Fixed-dose combination therapy in hypertension: Pros

High Blood Pressure and Cardiovascular Prevention

Volumn 19, Issue 2, 2012, Pages 55-57

  Taddei, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

antihypertensive therapy; fixed combination therapy; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CATECHOLAMINE BLOOD LEVEL; CHRONOTROPISM; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIXED DOSE COMBINATION THERAPY; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INOTROPISM; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84864849914     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11632180-000000000-00000     Document Type: Review

References (11)

1. Mancia G, De Backer G, Dominiczak A, et al. for the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Management of arterial hypertension. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25 (6): 1105-1187
2. Mancia G, Sega R, Milesi C, et al. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-457
3. Mancia G, Pessina AC, Trimarco B, et al., SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22 (12): 2387-2396
4. Mancia G, Laurent S, Agabiti-Rosei E, et al., European Society of Hypertension. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158
5. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly. Am J Hypertens 1997; 10 (Pt 1): 697-704
6. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64: 1279-1283
7. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: A comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8 (1): 45-50
8. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239-245
9. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530
10. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007; 120: 713-719
11. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010; 55: 399-407